With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two
pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the …

With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid
leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the …

Abstract Purpose of Review Over the past two decades, the introduction of tyrosine kinase
inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four …

The primary goal of tyrosine kinase inhibitor (TKI) therapy for patients with chronic myeloid
leukemia is survival, which is achieved by the vast majority of patients. The initial response …

More than 15 years ago, imatinib entered into the clinical practice as a “magic bullet”; from
that point on, the prognosis of patients affected by chronic myeloid leukemia (CML) became …

Chronic myeloid leukemia (CML) is triggered primarily by the t (9; 22)(q34. 13; q11. 23)
translocation. This reciprocal chromosomal translocation leads to the formation of the BCR …

The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid
leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be …

Introduction: With the discovery of imatinib mesylate nearly 20 years ago, tyrosine kinase
inhibitors (TKIs) were found to be effective in chronic myeloid leukemia (CML). TKI therapy …

国产甲磺酸伊马替尼治疗慢性髓性白血病慢性期早期疗效和安全性的前瞻性、多中心临床研究- PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Achieving early molecular response (EMR) has been shown to be associated with better
event free survival in patients with chronic phase chronic myeloid leukemia (CP-CML) on …